Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.56 |
| ▸ | CCR4 | P51679 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | OXTR | P30559 | 6/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573743 | 1.00 | CCR5 (0.56) | CCR5CCR4KCNH2OXTRPDCD1 | |
| SCHEMBL5572415 | 0.92 | CCR5 (0.60) | CCR5CCR4KCNH2OXTR | |
| SCHEMBL5572420 | 0.92 | CCR5 (0.60) | CCR5CCR4KCNH2OXTR | |
| SCHEMBL5575598 | 0.91 | CCR5 (0.57) | CCR5CCR4KCNH2 | |
| SCHEMBL5575607 | 0.91 | CCR5 (0.57) | CCR5CCR4KCNH2 | |
| SCHEMBL5573919 | 0.88 | CCR5 (0.56) | CCR5CCR4KCNH2OXTR | |
| SCHEMBL4596361 | 0.88 | CCR5 (0.56) | CCR5CCR4KCNH2OXTR | |
| SCHEMBL4598230 | 0.88 | CCR5 (0.59) | CCR5CCR4KCNH2 | |
| SCHEMBL5575419 | 0.88 | CCR5 (0.59) | CCR5CCR4KCNH2 | |
| SCHEMBL5575319 | 0.87 | CCR5 (0.72) | CCR5CCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885CCR4 2/4885KCNH2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.